Evogene Schedules Second Quarter 2026 Financial Results Release

Rhea-AI Summary

Evogene (Nasdaq: EVGN) will release its second quarter 2026 financial results on Tuesday, August 18, 2026. The company, which focuses on computational chemistry and generative design of small molecules for pharma and agriculture, will hold a management-hosted Zoom conference call that same day at 9:00 AM Eastern Time (4:00 PM Israel time) to discuss the results.

Investors must register in advance via the provided Veidan Conferencing link, and a replay of the entire conference will be available on Evogene's website a few days after the event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Zoom conference call scheduled for August 18, 2026, 9:00 AM ET

REHOVOT, Israel, July 30, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the second quarter 2026, on Tuesday, August 18, 2026.

Later that day, company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).

To attend the conference, please register in advance:

https://www.veidan-conferencing.com/evogene

The entire conference will be available online on the company's website a few days after.

About Evogene:

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com.

Contact

ir@evogene.com
Tel: +972-8-9311901

Logo - https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg 

View original content:https://www.prnewswire.com/news-releases/evogene-schedules-second-quarter-2026-financial-results-release-302838854.html

SOURCE Evogene

FAQ

When will Evogene (EVGN) release its Q2 2026 financial results?

Evogene will release its second quarter 2026 financial results on Tuesday, August 18, 2026. According to Evogene, the results publication will be followed by a management-hosted conference call later that day to discuss the quarterly performance and related updates.

What time is Evogene's (EVGN) Q2 2026 earnings conference call on August 18, 2026?

Evogene's Q2 2026 conference call is scheduled for 9:00 AM Eastern Time, 4:00 PM Israel time, on August 18, 2026. According to Evogene, company management will host the call to review and discuss the released quarterly financial results with investors and stakeholders.

How can investors register for Evogene's (EVGN) Q2 2026 Zoom conference call?

Investors can attend Evogene's Q2 2026 Zoom conference call by registering in advance at https://www.veidan-conferencing.com/evogene. According to Evogene, advance registration is required for access, after which participants will receive the necessary connection details for the scheduled event.

Will a replay of Evogene's (EVGN) Q2 2026 earnings call be available online?

Yes, a replay of Evogene's Q2 2026 earnings conference will be available online on the company’s website a few days after the call. According to Evogene, the entire conference will be accessible for investors who could not attend live.

What does Evogene (EVGN) focus on in its business operations?

Evogene is described as a pioneering company in computational chemistry, specializing in the generative design of small molecules. According to Evogene, its technology targets small-molecule development for both pharmaceutical and agricultural industries, supporting innovation across these two primary application domains.